Adalimumab (Humira) Prefilled Syringe
Adalimumab (Humira) is a fully human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease. It is presented in pre-filled syringes with measured doses for retail sale, qualifying as an immunological product under tariff item 3002.15.00. This item covers immunological products put up in measured doses or in forms or packings for retail sale.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If the product is not put up in measured doses or retail packings
This subheading covers immunological products not in measured doses or retail packings.
If classified as a medicament rather than an immunological product
Medicaments consisting of mixed or unmixed products for therapeutic use may fall under heading 30.04.
If the product is an unmixed immunological product
Unmixed immunological products are classified under subheading 3002.13.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Ensure the product is clearly labelled as a measured dose for retail sale to qualify for this tariff item
• Have the Certificate of Analysis and product monograph ready for CBSA review
• Verify whether a Drug Identification Number (DIN) is required by Health Canada before importation
Related Products under Tariff item 3002.15.00
Adalimumab Prefilled Syringe for Psoriasis Treatment
Adalimumab, sold under the brand Humira, is a TNF inhibitor monoclonal antibody presented in 40 mg prefilled syringes for retail sale. It is used prophylactically to manage autoimmune psoriasis flares. As an immunological product put up in measured doses for retail sale, it is classified under tariff item 3002.15.00.
AstraZeneca Vaxzevria COVID-19 Vaccine
Vaxzevria is a COVID-19 vaccine using a chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein, triggering an immune response. It is supplied in multi-dose vials for retail distribution, qualifying as an immunological product under tariff item 3002.15.00.
Atezolizumab (Tecentriq) Concentrate
Atezolizumab (Tecentriq) is a humanized monoclonal antibody targeting PD-L1, used in immunotherapy for bladder cancer and other malignancies. It is supplied as a concentrate for infusion in measured-dose vials for retail sale, meeting the criteria for tariff item 3002.15.00. This product directly regulates immunological processes through checkpoint inhibition.
Bavarian Nordic Imvamune Smallpox Vaccine
Imvamune is a non-replicating modified vaccinia Ankara vaccine for smallpox and mpox protection. It is an immunological product presented in measured doses for retail sale, fitting tariff item 3002.15.00.
Bevacizumab (Avastin) IV Solution
Bevacizumab (Avastin) is a humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF), used in treating colorectal and lung cancers. It is presented as an IV solution in measured-dose vials for retail sale, qualifying under tariff item 3002.15.00 as an immunological product. The product regulates immunological processes via angiogenesis inhibition.
Bevacizumab Biosimilar Vial for Oncology
Bevacizumab, an Avastin biosimilar, is a VEGF monoclonal antibody supplied in 100 mg/4 ml vials for retail infusion in oncology. It modulates angiogenesis through immune regulation. This immunological product, in measured doses for retail sale, is classified under tariff item 3002.15.00.